<DOC>
	<DOCNO>NCT00591890</DOCNO>
	<brief_summary>Single arm , open label , Phase IB study indibulin capsule subject advance solid tumor ; eligible subject baseline PET scan show standardized uptake value ( SUV ) ≥5.0 ≥1 lesion 18F-FDG ( fluorine-18-labeled deoxyglucose ) scale .</brief_summary>
	<brief_title>Phase IB Study Indibulin Using Positron-Emission Tomography ( PET ) Scans</brief_title>
	<detailed_description />
	<criteria>1 . Histological cytological confirmation advance cancer , refractory standard therapy . 2 . Received least one prior therapy require additional treatment . 3 . ≥18 year age . 4 . ECOG performance score ≤ 2 ( see Appendix 3 ) . 5 . At least one measurable lesion define RECIST ( Response evaluation criterion solid tumor ) guideline ( see Appendix 4 ) . If measurable disease restrict solitary lesion , neoplastic nature confirm cytology/histology . Measurable lesion must NOT previously irradiate field injected biological agent . 6 . PET scan show standardized uptake value ( SUV ) ≥5.0 least 1 lesion 18FFDG ( fluorine18labeled deoxyglucose ) scale . 7 . Life expectancy ≥12 week . 8 . Adequate bone marrow , liver renal function assess follow laboratory requirement , conduct &lt; 2 week prior Day 1 : Creatinine ≤1.5 × upper limit normal ( ULN ) calculate creatinine clearance ≥50 cc/minute Total bilirubin ≤1.5 × ULN Alanine transaminase ( ALT ) aspartate transaminase ( AST ) ≤2.5 × ULN White blood cell count ≥3.0 × 109/L Absolute neutrophil count ( ANC ) ≥1.5 × 109/L Platelets ≥100 × 109/L Hemoglobin ≥10 g/dL 9 . Ability tolerate repeat blood sample adequate vascular access . 10 . Serum glucose level ≤200 mg/dL . 11 . Provide write informed consent compliance ZIOPHARM policy Independent Ethics Committee jurisdiction site . 12 . Subjects childbearing potential must agree use barrier method contraception throughout study 3 month study drug administration . 1 . New York Heart Association ( NYHA ) functional class ≥3 myocardial infarction within 6 month ( see Appendix 5 ) . 2 . Uncontrolled diabetes mellitus 3 . Uncontrolled cardiac arrhythmia asymptomatic atrial fibrillation . 4 . Pregnancy and/or lactation . 5 . Uncontrolled systemic infection ( documented microbiological study ) 6 . Any anticancer immunological therapy study within 4 week study entry . Mitomycin C nitrosureas give within 6 week study entry . 7 . Radiotherapy study within 3 week study entry . 8 . Surgery within 4 week start study drug exclude tumor biopsy pharmacodynamic parameter . 9 . Investigational drug therapy outside trial within 4 week study entry . 10 . History invasive second primary malignancy diagnose within previous 3 year , except Stage I endometrial/cervical carcinoma prostate carcinoma treat surgically , nonmelanoma skin cancer . 11 . Substance abuse , medical , psychological social condition may interfere subject 's participation study evaluation study result 12 . Any condition unstable could jeopardize safety subject his/her compliance study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>